You're intelligence (or lack thereof) is really shining here. Read AMRN's press release... it is like a quick Phase 1 study, and if successful, they will probably initiate a larger, more conclusive one.
biotech researcher,, do you believe dr.bhattman would align his lifelong experience with horse crap,,, researcher,, when I read your post,, even I think im bright,, keep coming back,,
biotech... Why do you say this? Honest question. No games. Is it because the population is small? Is it a waste of time in your mind? As it relates to studying medications for any given disease start there is a format to follow. P1-P3, with P4 studies included which most often are post marketing requirements by the FDA. If your critique is about the trial size, then you are out of luck. There isn’t a way around that. It’s quite important to to run a “proof of concept” study first. This determines if there is a need to proceed further or not.
News 
Market Data 
Discover 
